Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
Stock Summary
Top Correlated Resources
000640.KS
Top 10 Correlated ETFs
000640.KS
Top 10 Correlated Stocks
000640.KS
Financial details
Company Rating
Buy
Market Cap
631.32B
Income
48.97B
Revenue
956.81B
Book val./share
154143.95
Cash/share
22598.63
Dividend
1500
Dividend %
1.49%
Employees
87
Optionable
No
Shortable
Yes
Earnings
14 Nov 2022
P/E
12.9
Forward P/E
-
PEG
-2.27
P/S
0.66
P/B
0.66
P/C
4.47
P/FCF
12.55
Quick Ratio
0.27
Current Ratio
0.7
Debt / Equity
0.18
LT Debt / Equity
0.17
-
-
EPS (TTM)
11.52K
EPS next Y
-
EPS next Q
-
EPS this Y
-97.85%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-35.9%
Revenue last 5Y
5.02%
Revenue Q/Q
16.92%
EPS Q/Q
-3191.73%
-
-
-
-
SMA20
-5.92%
SMA50
-5.23%
SMA100
-9.92%
Inst Own
-
Inst Trans
-
ROA
3%
ROE
5%
ROC
0.04%
Gross Margin
31%
Oper. Margin
5%
Profit Margin
5%
Payout
19%
Shs Outstand
6.25M
Shs Float
3.01M
-
-
-
-
Target Price
-
52W Range
92100.0-119500.0
52W High
-15.48%
52W Low
+9.66%
RSI
46.61
Rel Volume
0.68
Avg Volume
4.98K
Volume
3.37K
Perf Week
-2.42%
Perf Month
-7.76%
Perf Quarter
-7.76%
Perf Half Y
-9.42%
-
-
-
-
Beta
0.7051
-
-
Volatility
1600%, 3205.69%
Prev Close
0.5%
Price
101000
Change
4.45%
Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 112.65K | 115.21K | 125.39K | 128.95K | 8.41K | |
| Net income per share | 5.31K | -26.71K | 3.22K | 26.72K | 574.56 | |
| Operating cash flow per share | 13.78K | 9.5K | 15.77K | 13.92K | 1.25K | |
| Free cash flow per share | 8.99K | 4.28K | 8.41K | 4.83K | 499.11 | |
| Cash per share | 29.47K | 18.48K | 23.06K | 23.78K | 1.51K | |
| Book value per share | 148.97K | 119.61K | 121.39K | 146.3K | 9.2K | |
| Tangible book value per share | 144.89K | 112.03K | 114.24K | 138.87K | 8.31K | |
| Share holders equity per share | 148.97K | 119.61K | 121.39K | 146.3K | 9.2K | |
| Interest debt per share | 67K | 62.37K | 78.51K | 82.29K | 5.23K | |
| Market cap | 916.02B | 638.38B | 580.07B | 683.4B | 10374.51B | |
| Enterprise value | 1135.04B | 901.76B | 961.76B | 1082.52B | 10812.46B | |
| P/E ratio | 28.15 | -3.89 | 29.35 | 4.21 | 172.13 | |
| Price to sales ratio | 1.33 | 0.9 | 0.75 | 0.87 | 11.76 | |
| POCF ratio | 10.85 | 10.95 | 5.99 | 8.08 | 79.14 | |
| PFCF ratio | 16.64 | 24.32 | 11.23 | 23.27 | 198.15 | |
| P/B Ratio | 1 | 0.87 | 0.78 | 0.77 | 10.75 | |
| PTB ratio | 1 | 0.87 | 0.78 | 0.77 | 10.75 | |
| EV to sales | 1.64 | 1.28 | 1.25 | 1.38 | 12.26 | |
| Enterprise value over EBITDA | 13.79 | -6.58 | 9.87 | 4.6 | 79.07 | |
| EV to operating cash flow | 13.44 | 15.46 | 9.94 | 12.8 | 82.48 | |
| EV to free cash flow | 20.62 | 34.35 | 18.63 | 36.87 | 206.52 | |
| Earnings yield | 0.04 | -0.26 | 0.03 | 0.24 | 0.01 | |
| Free cash flow yield | 0.06 | 0.04 | 0.09 | 0.04 | 0.01 | |
| Debt to equity | 0.19 | 0.21 | 0.22 | 0.28 | 0.22 | |
| Debt to assets | 0.37 | 0.41 | 0.45 | 0.41 | 0.42 | |
| Net debt to EBITDA | 2.66 | -1.92 | 3.92 | 1.7 | 3.2 | |
| Current ratio | 1.1 | 0.91 | 0.76 | 0.95 | 0.77 | |
| Interest coverage | 4.44 | 4.2 | 3.94 | 4.23 | 5.35 | |
| Income quality | 2.6 | -0.36 | 4.9 | 0.52 | 2.17 | |
| Dividend Yield | 0.01 | 0.01 | 0.01 | 0.01 | 0 | |
| Payout ratio | 0.19 | -0.04 | 0.31 | 0.04 | 0.15 | |
| Sales general and administrative to revenue | 0.03 | 0.03 | 0.04 | 0.05 | 0.04 | |
| Research and developement to revenue | 0.03 | 0.03 | 0.03 | 0.02 | 0.01 | |
| Intangibles to total assets | 0.02 | 0.04 | 0.03 | 0.03 | 0.07 | |
| Capex to operating cash flow | -0.35 | -0.55 | -0.47 | -0.65 | -0.6 | |
| Capex to revenue | -0.04 | -0.05 | -0.06 | -0.07 | -0.09 | |
| Capex to depreciation | -1.27 | -1.33 | -0.99 | -1.04 | -1.33 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 133.42K | 268.13K | 93.78K | 296.6K | 10.91K | |
| ROIC | 0.05 | 0.05 | 0.06 | 0.04 | 0.05 | |
| Return on tangible assets | 0.02 | -0.14 | 0.02 | 0.11 | 0.04 | |
| Graham Net | -53.2K | -57.35K | -70.5K | -72.12K | -4.86K | |
| Working capital | 30.95B | -28.2B | -99.11B | -19B | -108.73B | |
| Tangible asset value | 887.79B | 687.64B | 701.25B | 843.58B | 871.82B | |
| Net current asset value | -191.28B | -214.47B | -296.39B | -292.96B | -347.8B | |
| Invested capital | 0.44 | 0.51 | 0.63 | 0.55 | 0.56 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 29.18B | 29.47B | 33.1B | 33.69B | 29.78B | |
| Average inventory | 78.45B | 80.51B | 77.16B | 79.65B | 77.85B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 20.26 | 19.53 | 23.51 | 23.59 | 15.72 | |
| Days of inventory on hand | 63.44 | 62.94 | 54 | 55.76 | 46.23 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 18.02 | 18.69 | 15.53 | 15.47 | 23.22 | |
| Inventory turnover | 5.75 | 5.8 | 6.76 | 6.55 | 7.89 | |
| ROE | 0.04 | -0.22 | 0.03 | 0.18 | 0.06 | |
| Capex per share | -4.8K | -5.23K | -7.36K | -9.09K | -750.54 |
Quarterly Fundamentals Overview
Last date of statement is 2022-06-30 for Q2
| Metric | History | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 35.48K | 39.26K | 2.91K | 2.77K | 41.74K | |
| Net income per share | 2.6K | 10.32K | -237.32 | -47.87 | 1.48K | |
| Operating cash flow per share | 4.49K | 8.56K | 545.29 | 79.13 | 6.27K | |
| Free cash flow per share | 2.83K | 5.55K | 221.57 | -208.89 | 2.5K | |
| Cash per share | 28.18K | 25.25K | 1.97K | 0 | 22.6K | |
| Book value per share | 150.02K | 162.06K | 11.99K | 11.85K | 154.14K | |
| Tangible book value per share | 141.6K | 147.77K | 10.83K | 12.09K | 137.81K | |
| Share holders equity per share | 150.02K | 162.06K | 11.99K | 11.85K | 154.14K | |
| Interest debt per share | 83.42K | 88.19K | 6.62K | -45.35 | 84.9K | |
| Market cap | 743.95B | 707.41B | 9258.98B | 9178.47B | 641.05B | |
| Enterprise value | 1143.19B | 1114.56B | 9696.93B | 9178.47B | 1070.63B | |
| P/E ratio | 11.69 | 2.82 | -121.14 | -595.37 | 17.31 | |
| Price to sales ratio | 3.42 | 2.97 | 39.55 | 41.11 | 2.46 | |
| POCF ratio | 27.06 | 13.6 | 210.9 | 1.44K | 16.36 | |
| PFCF ratio | 42.93 | 21.01 | 519.03 | -545.73 | 41.03 | |
| P/B Ratio | 0.81 | 0.72 | 9.59 | 9.62 | 0.66 | |
| PTB ratio | 0.81 | 0.72 | 9.59 | 9.62 | 0.66 | |
| EV to sales | 5.26 | 4.68 | 41.42 | 41.11 | 4.1 | |
| Enterprise value over EBITDA | 53.54 | 17.98 | -698.17 | -1.29K | 123.06 | |
| EV to operating cash flow | 41.59 | 21.43 | 220.87 | 1.44K | 27.32 | |
| EV to free cash flow | 65.96 | 33.1 | 543.58 | -545.73 | 68.53 | |
| Earnings yield | 0.02 | 0.09 | 0 | 0 | 0.01 | |
| Free cash flow yield | 0.02 | 0.05 | 0 | 0 | 0.02 | |
| Debt to equity | 0.21 | 0.19 | 0.22 | 0 | 0.18 | |
| Debt to assets | 0.42 | 0.42 | 0.42 | 0.43 | 0.43 | |
| Net debt to EBITDA | 18.7 | 6.57 | -31.53 | 0 | 49.38 | |
| Current ratio | 0.87 | 0.76 | 0.77 | 0.79 | 0.7 | |
| Interest coverage | 0 | 0 | -4.2 | 0.55 | -2.64 | |
| Income quality | 1.73 | 0.83 | -2.3 | -1.65 | 4.23 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | -0.16 | 0 | 0 | |
| Sales general and administrative to revenue | 0.04 | 0.04 | 0.05 | 0.28 | 0.04 | |
| Research and developement to revenue | 0.01 | 0.01 | 0.01 | 0 | 0.01 | |
| Intangibles to total assets | 0.03 | 0.06 | 0.07 | 0 | 0.07 | |
| Capex to operating cash flow | -0.37 | -0.35 | -0.59 | -3.64 | -0.6 | |
| Capex to revenue | -0.05 | -0.08 | -0.11 | -0.1 | -0.09 | |
| Capex to depreciation | -3.55 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 93.64K | 194K | 8K | 3.57K | 71.64K | |
| ROIC | 0.02 | 0.02 | 0.01 | 0 | 0.01 | |
| Return on tangible assets | 0.01 | 0.04 | -0.01 | 0 | 0.01 | |
| Graham Net | -72.98K | -88.32K | -6.33K | -9.02K | -87.24K | |
| Working capital | -58.56B | -119.83B | -108.73B | -97.37B | -161.51B | |
| Tangible asset value | 867.03B | 897.3B | 871.82B | 0 | 861.86B | |
| Net current asset value | -283.76B | -349.97B | -347.8B | -366.42B | -366.15B | |
| Invested capital | 0.56 | 0.54 | 0.56 | 0 | 0.56 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 22.01 | 18.26 | 14.33 | 0 | 20.93 | |
| Days of inventory on hand | 51.33 | 50.59 | 42.14 | 0 | 48.25 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 4.09 | 4.93 | 6.28 | 0 | 4.3 | |
| Inventory turnover | 1.75 | 1.78 | 2.14 | 0 | 1.87 | |
| ROE | 0.02 | 0.06 | -0.02 | 0 | 0.01 | |
| Capex per share | -1.66K | -3.02K | -323.72 | -288.03 | -3.77K |
Frequently Asked Questions
What is Dong-A Socio Holdings Co., Ltd. stock symbol ?
Dong-A Socio Holdings Co., Ltd. is a US stock and trading under the symbol 000640.KS
What is Dong-A Socio Holdings Co., Ltd. stock quote today ?
Dong-A Socio Holdings Co., Ltd. stock price is $101000 today.
Is Dong-A Socio Holdings Co., Ltd. stock public?
Yes, Dong-A Socio Holdings Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 4.98K
- Market Capitalization 631.32B
- Employee 87
- Headquarters Seoul,US
- IPO Date 2005-09-29
-
Website
https://www.donga.co.kr 
Dong-A Socio Holdings Co., Ltd. engages in the pharmaceutical business in South Korea and internationally. It offers Bacchus, Benachio, and Tempo; infection management products; imaging equipment, such as FX-V1 and CLS-S7 for surgery and diagnosis; and MEDIFLIX, a medical knowledge-sharing platform. The company provides business management services; CMO services, including pre-clinical study, clinical trial, and commercial production of antibodies and recombinant proteins; maintenance, repair, and operation; quarantine; and military logistics services; and packaging and parcel delivery services. In addition, it offers mineral water under the Gayasan Cheonnyeonsu brand; POCARI SWEAT; Narangd cider; Oronamin C; Oran-C bio-PET; and STP2104, an mRNA based COVID-19 vaccine, which is in phase I clinical trial. Further, the company engages in the construction of industrial facilities, such as bio, pharmaceutical, food, logistics warehouses, education/research facilities, work/sales facilities, and public facilities; provides design, maintenance, and asset development services. Additionally, it provides IT systems development and maintenance. The company was founded in 1932 and is headquartered in Seoul, South Korea.
